Global Yellow Fever Vaccines Market Size By Type (Powder, Liquid), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Yellow Fever Vaccines Market was valued at USD 485 million in 2023 and is projected to reach USD 734 million by 2031, growing at a CAGR of 5.4% during the forecast period from 2023 to 2031. The rising incidence of yellow fever in endemic regions, especially in sub-Saharan Africa and parts of South America, along with increased international travel and the resurgence of mosquito-borne illnesses, has significantly fueled the demand for yellow fever vaccines. Heightened awareness of epidemic preparedness, robust support from international health agencies like WHO and GAVI, and ongoing research to improve vaccine efficacy and shelf life are major contributors to the market's growth.

Drivers:

Increasing Global Immunization Initiatives:

Global vaccination campaigns, particularly in Africa and Latin America, have received substantial support from government health departments and organizations like UNICEF and PAHO, driving mass immunization efforts against yellow fever.

Rising International Travel:

The uptick in global travel to and from yellow fever-endemic areas has created mandatory vaccination requirements for travelers, which bolsters vaccine demand and market growth.

Resurgence of Vector-borne Diseases:

Changing climatic conditions and urbanization are intensifying the spread of vector-borne diseases, leading to yellow fever outbreaks and stimulating global preventive vaccination campaigns.

Restraints:

Limited Vaccine Supply:

Yellow fever vaccine production is concentrated among a few manufacturers, creating risks of supply shortages during outbreaks or unexpected surges in demand.

Adverse Effects and Contraindications:

Though rare, serious adverse reactions and contraindications—especially in infants, pregnant women, and immunocompromised individuals—can restrict vaccine uptake and pose challenges for public health distribution.

Opportunity:

Development of Next-Generation Vaccines:

Research into thermostable, dose-sparing, and combination vaccines presents new opportunities to expand access in remote and high-risk areas with limited cold-chain capabilities.

Expansion in Emerging Markets:

Emerging economies in Southeast Asia, the Middle East, and parts of Central Africa present untapped opportunities for yellow fever vaccination programs as governments enhance disease surveillance and response infrastructures.

Market by System Type Insights:

Based on vaccine type, the live attenuated vaccine segment held the largest share in 2023. These vaccines are WHO-prequalified and offer long-lasting immunity with a single dose. Although inactivated vaccine research is underway, live attenuated vaccines remain the most reliable and widely used globally due to their high efficacy.

Market by End-use Insights:

The public health sector accounted for the largest end-use market share in 2023, driven by widespread government and international procurement and vaccination campaigns. Meanwhile, the private travel clinics segment is expected to register steady growth due to international travel regulations and pre-travel health requirements.

Market by Regional Insights:

Africa emerged as the leading regional market in 2023, driven by the endemic presence of yellow fever and substantial immunization programs supported by WHO and GAVI. Latin America followed, with countries like Brazil and Peru investing in mass immunization. However, Asia-Pacific is projected to grow fastest, fueled by increased surveillance, preparedness initiatives, and global traveler inflow.

Competitive Scenario:

Key players in the global yellow fever vaccines market include:

Sanofi Pasteur

Bio-Manguinhos (Fiocruz)

Institut Pasteur de Dakar

Chumakov Institute of Poliomyelitis and Viral Encephalitides

Wuhan Institute of Biological Products Co., Ltd.

Serum Institute of India

These companies focus on expanding production capabilities, regulatory approvals, and collaborating with global health agencies. For example:

In 2023, Sanofi Pasteur announced a strategic partnership with WHO to increase yellow fever vaccine production under the EYE (Eliminate Yellow fever Epidemics) strategy.

Bio-Manguinhos scaled up its production units in Brazil to meet domestic and export demands.

Scope of Work – Global Yellow Fever Vaccines Market

Key Market Developments:

June 2023: WHO expanded the EYE strategy to include additional 10 high-risk African countries, spurring procurement from existing vaccine suppliers.

March 2024: Serum Institute of India filed for WHO prequalification for its yellow fever vaccine, marking its entry into the global supply chain.

September 2024: Bio-Manguinhos received approval for expanded production facilities, boosting Brazil's domestic supply resilience and export capability.

FAQs:

What is the current market size of the Global Yellow Fever Vaccines Market?

The market was valued at USD 485 million in 2023.

What is the major growth driver of the Global Yellow Fever Vaccines Market?

The major growth driver is the expansion of global immunization campaigns and rising travel to endemic regions.

Which is the largest region during the forecast period in the Global Yellow Fever Vaccines Market?

Africa is the largest regional market due to endemic outbreaks and robust vaccination efforts.

Which segment accounted for the largest market share in the Global Yellow Fever Vaccines Market?

The live attenuated vaccine segment accounted for the largest share in 2023.

Who are the key market players in the Global Yellow Fever Vaccines Market?

Key players include Sanofi Pasteur, Bio-Manguinhos, Institut Pasteur de Dakar, and Serum Institute of India.